Strategic Shape Diagnostic
Tool / Research Product
Sells to researchers and labs. Revenue is possible without clinical clearance. TR companies generate value through commercial metrics — revenue, customer count, retention rates, and market share — not through clinical pipeline advancement. The buyer set, the valuation framework, and the deal structures are all distinct from companies developing therapeutics or medical products for regulatory approval.
Deal Structures
How this shape transacts
Commercial acquisition priced on revenue multiples, not pipeline risk-adjusted NPV
Strategic partnership with procurement agreements and volume commitments
Service agreements and OEM relationships with larger platform companies
Technology licensing for integration into commercial research workflows
Contradictions
Common contradictions for TR companies
Contradiction 01
Conflating research tool revenue with drug development value — a company generating revenue from selling reagents to labs cannot claim the valuation framework of a company developing therapeutics
Contradiction 02
Pitching to drug-development investors when the business model is commercial products for the research market
Contradiction 03
Describing the business as a platform company when the revenue is product sales to a fragmented buyer base
Counterparty View
What counterparties expect
Counterparties evaluate TR companies on commercial metrics, not pipeline data. They look for revenue growth, gross margins, customer concentration, competitive moat, and switching costs. The acquirer set is companies looking to expand their research tools portfolio — not pharma companies looking for clinical assets. Valuations are based on revenue or EBITDA multiples, not on risk-adjusted NPV of clinical programs.
Find out if this is your shape.
The Shape Diagnostic classifies your company into one of seven archetypes in seven minutes.
Free classification · $49 full report